- Pluristem Therapeutics (NASDAQ:PSTI) is selected as a member of the CRISPR-IL consortium, a group funded by the Israeli Innovation Authority.
- CRISPR-IL brings together the leading experts in life science and computer science to develop artificial intelligence (AI) based end-to-end genome-editing solutions.
- These next-generation, genome editing products for human, plant, and animal DNA, have applications in the pharma, agriculture, and aquaculture industries.
- CRISPR is a genome-editing technology for detecting and modifying DNA sequences and is used as a tool to enable genetic changes.
- Shares are up 2% premarket.